AZD2098

AZD2098 is a potent and selective CC-chemokine receptor 4 (CCR4) inhibitor with pIC50s of 7.8, 8.0, 8.0 and 7.6 for human, rat, mouse and dog respectively, used for asthma research[1][2].

Product Specifications

CAS Number

[566203-88-1]

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

CCR

Type

Reference compound

Related Pathways

GPCR/G Protein; Immunology/Inflammation

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology; Endocrinology

Assay Protocol

https://www.medchemexpress.com/AZD2098.html

Purity

99.91

Solubility

DMSO : 100 mg/mL (ultrasonic) |Ethanol : 5 mg/mL (ultrasonic; warming; heat to 60°C)

Smiles

O=S(C1=CC=CC(Cl)=C1Cl)(NC2=NC=CN=C2OC)=O

Molecular Formula

C11H9Cl2N3O3S

Molecular Weight

334.18

Precautions

H302, H315, H319, H335

References & Citations

[1]Kindon N, et al. Discovery of AZD-2098 and AZD-1678, Two Potent and Bioavailable CCR4 Receptor Antagonists. ACS Med Chem Lett. 2017 Sep 1;8 (9) :981-986.|[2]Asher Mullard. Cancer charity sees success re-prioritizing industry's shelved compounds. Nat Rev Drug Discov. 2014 May;13 (5) :319-21.